A tumour is any abnormal mass of tissue that forms when cells grow and divide more than they should, or when old cells survive instead of dying on schedule. Not every tumour is cancer. Tumours fall broadly into two categories, benign and malignant, and only the malignant ones qualify as cancer. The distinction matters enormously for treatment and prognosis, but the line between the two is less clean-cut than most people assume.
Benign Versus Malignant
A benign tumour grows in a contained way. It stays put, usually surrounded by a capsule of tissue that keeps it separated from its neighbours. It does not invade surrounding structures and it does not spread to distant parts of the body. Common examples include uterine fibroids, skin moles (nevi), and many types of polyps. A benign tumour’s cells still look relatively normal under a microscope and tend to grow slowly.
A malignant tumour, by contrast, is what we call cancer. Its cells look abnormal, divide faster, and have acquired the ability to invade nearby tissue and eventually travel to other organs. That spreading process, called metastasis, is the hallmark that separates cancer from a benign growth. Research modelling tumour development suggests that benign tumour cells carry fewer genetic mutations than malignant cells, and that the additional mutations in malignant cells are what unlock invasion and metastasis as new capabilities.1PubMed. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis
So if your doctor says you have a tumour, the first and most important question is whether it is benign or malignant. The word “tumour” alone does not mean cancer, and hearing it should not trigger panic before you know which type you are dealing with.
When a Benign Tumour Is Still a Problem
Benign does not always mean harmless. A non-cancerous tumour in the brain, for instance, can cause serious neurological problems simply because the skull leaves no room for it to expand. Meningiomas and acoustic neuromas are histologically benign, meaning they are not cancer under the microscope, yet they can compress brain tissue, impair vision or hearing, and require complex surgery.2PubMed. Common Histologically Benign Tumors of the Brain The danger comes from location, not from malignancy.
Other benign tumours cause problems by producing hormones. A benign adrenal tumour can flood the body with cortisol; a benign pituitary tumour can overproduce growth hormone. These growths are not cancer, but they absolutely require treatment. The takeaway is that “benign” means “not cancer,” and while that is genuinely good news compared to a malignant diagnosis, it does not automatically mean you can ignore the growth.
How a Normal Cell Becomes a Tumour
Every cell in your body carries genes that tell it when to grow, when to stop, and when to die. Two broad families of genes are central to cancer biology: oncogenes, which promote growth, and tumour suppressor genes, which act as brakes. When mutations knock out the brakes or jam the growth signals into the “on” position, cells can begin dividing out of control.3PubMed Central. Oncogenes and tumor suppressor genes: functions and roles in cancers
Not every mutation leads to cancer. Most mutated cells are caught by the body’s repair systems or killed off by the immune system. A tumour forms only when enough mutations accumulate in the right combination. Animal studies mapping the progression from normal tissue to cancer have shown a stepwise sequence: first overgrowth (hyperplasia), then increasingly abnormal-looking cells (dysplasia), then a contained early-stage lesion (carcinoma in situ), and finally invasive cancer.4PubMed. Characterization of breast cancer progression in the rat This gradual escalation is why screening programs exist. Catching a growth at the dysplasia or carcinoma-in-situ stage can prevent it from ever becoming a full-blown cancer.
What drives these mutations in the first place? Some are inherited, some are caused by environmental exposures like tobacco smoke or ultraviolet radiation, and some are caused by infections. Viruses and bacteria such as HPV, hepatitis B and C, Epstein-Barr virus, and the stomach bacterium Helicobacter pylori all contribute to the development of specific cancers.5PubMed Central. Causal role of infectious agents in cancer: An overview The HPV vaccine, for example, works by preventing the infection that triggers most cervical cancers.
What Metastasis Actually Involves
The feature that makes malignant tumours so dangerous is their ability to spread. Metastasis is not a single event but a chain of steps: tumour cells first invade the tissue around them, then break into a blood vessel or lymphatic channel, travel through the circulation, exit at a distant site, and establish a new colony of cancer cells there.6PubMed Central. Initial steps of metastasis: cell invasion and endothelial transmigration Each of those steps is difficult for a cancer cell; the vast majority of cells that enter the bloodstream die before they can colonise a new organ. But the ones that survive create secondary tumours that are often harder to treat than the original.
The local environment around the tumour plays a role in enabling this process. Cancers create an acidic, low-oxygen microenvironment that can promote invasion and entry into blood vessels.7PubMed. Tumor pH and metastasis: a malignant process beyond hypoxia Benign tumours do not develop these capabilities, which is one of the fundamental biological reasons they stay put.
The Tumour’s Surrounding Ecosystem
A cancer is not just a ball of abnormal cells. It exists within a complex neighbourhood of immune cells, blood vessels, connective tissue cells, and signalling molecules collectively called the tumour microenvironment. These surrounding cells were once thought to be innocent bystanders, but they turn out to play active roles in cancer’s progression.8PubMed. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
Immune cells, for instance, should theoretically attack cancer. In many cases, though, the tumour microenvironment hijacks them instead. Immune cells in and around a tumour can be reprogrammed to suppress anti-tumour responses and even promote further growth.9PubMed Central. The tumor microenvironment and its role in promoting tumor growth This is exactly why modern immunotherapy drugs work: they strip away the tumour’s ability to hide from or co-opt the immune system, reawakening the body’s natural defences.
Cancers That Never Form a Solid Tumour
The word “tumour” conjures an image of a lump you can see or feel, but some cancers do not form solid masses at all. Leukaemia, for example, is a cancer of blood-forming cells. It originates in the bone marrow and floods the bloodstream with abnormal white blood cells. There is no single lump to point to, yet it is unquestionably cancer. Likewise, certain lymphomas can spread diffusely through the lymphatic system without forming a discrete mass in the early stages.
This is an important reason why “tumour” and “cancer” are not interchangeable words. Some tumours are not cancer (benign growths), and some cancers are not tumours (blood cancers). The overlap is large, since most cancers do form solid tumours, but neither term fully contains the other.
Not Every Lump Is a Tumour
When you discover a lump or your doctor spots a mass on a scan, it does not necessarily mean abnormal cell growth is happening. Abscesses, which are walled-off pockets of infection, can look remarkably similar to tumours on imaging. In the brain, a bacterial abscess can mimic a cancerous tumour on a standard MRI, and specialised imaging techniques are often needed to tell them apart.10PubMed. Brain abscess and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion-weighted MR imaging The same challenge arises in the liver, where an abscess can resemble a cystic or dying tumour.11PubMed. Diffusion-weighted MR imaging of the liver: distinguishing hepatic abscess from cystic or necrotic tumor
Cysts, which are fluid-filled sacs, are another common mimic. Most cysts are not tumours at all. Ovarian cysts, for example, are extremely common in women of reproductive age, and the overwhelming majority resolve on their own. Swollen lymph nodes from an infection, fatty lumps called lipomas, and collections of scar tissue can all feel like masses. The point is that finding a lump is a reason to get it checked, not a reason to assume the worst.
How Doctors Figure Out What a Growth Is
The process of determining whether a mass is benign, malignant, or something else entirely typically starts with imaging. CT scans, MRIs, and ultrasounds can reveal a lot about a growth’s location, shape, and internal structure. For bone tumours in the spine, for example, a combination of patient age, where exactly the tumour sits, and the pattern of bone destruction visible on CT and MRI helps doctors narrow down the possibilities.12PubMed. Diagnostic imaging of solitary tumors of the spine: what to do and say
Imaging alone, however, usually cannot give a definitive answer. That requires a biopsy, in which a sample of the growth is removed and examined under a microscope. Pathologists look at cell shape, organisation, and how rapidly cells are dividing. When those features are ambiguous, they add specialised stains and molecular tests. In thyroid nodules, for instance, markers such as galectin-3 and CK19 help distinguish benign from malignant tissue, reducing unnecessary surgery for nodules that turn out to be harmless.13PubMed Central. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules For soft tissue tumours sampled by needle biopsy, where the amount of tissue available is small, pathologists lean even more heavily on molecular and genetic testing to reach a specific diagnosis.14Modern Pathology. Limited biopsies of soft tissue tumors: the contemporary role of immunohistochemistry and molecular diagnostics
The Push to Stop Calling Some Growths “Cancer”
Here is where the picture gets genuinely complicated. Some growths that are technically classified as cancer under the microscope behave so slowly that they may never cause harm during a person’s lifetime. Small, low-grade thyroid cancers and certain prostate cancers fall into this category. A working group convened by the U.S. National Cancer Institute argued that calling these indolent lesions “cancer” does more harm than good, because it pushes patients and doctors toward aggressive treatment that may not be needed.15PubMed Central. Addressing overdiagnosis and overtreatment in cancer: a prescription for change Their proposal was to rename these low-risk lesions using terms that do not include the word “cancer.”16BMJ. Don’t call low risk lesions cancer, experts say
This is not just a semantic debate. When people hear the word “cancer,” fear takes over, and that fear drives decisions. A randomised trial tested the effect of different terminology on patients told they had a low-risk papillary thyroid lesion. Those whose diagnosis was described as “papillary thyroid cancer” reported meaningfully higher anxiety than those told they had a “papillary lesion” or “abnormal cells,” even though the underlying condition was identical.17JAMA Otolaryngology–Head & Neck Surgery. Effect of a Change in Papillary Thyroid Cancer Terminology on Anxiety Levels and Treatment Preferences Language shapes treatment choices: a patient who hears “cancer” is more likely to opt for surgery even when active surveillance would be equally safe.
Can Tumours Shrink on Their Own?
It is rare, but documented. Spontaneous tumour regression, where a tumour partially or completely disappears without treatment, has been observed across several cancer types. The leading explanations centre on the immune system suddenly recognising and attacking the tumour, sometimes triggered by infection, fever, or other immune-stimulating events. Hormonal changes and the cutting off of a tumour’s blood supply have also been proposed as mechanisms.18PubMed Central. The phenomenon of spontaneous tumor regression in breast cancer
Spontaneous regression is genuinely fascinating, but it is not something you should ever count on. The phenomenon is exceedingly uncommon, and researchers study it primarily because understanding how the immune system occasionally wins might reveal new therapeutic strategies. If you have been diagnosed with a tumour, waiting and hoping for spontaneous regression is not a rational plan. But the fact that it happens at all underscores just how central the immune system is to controlling abnormal cell growth.
Why Whales Rarely Get Cancer
Tumour biology has an evolutionary dimension that raises a paradox. Larger animals with more cells should, in theory, have a higher chance of one of those cells turning cancerous. Yet whales, elephants, and other massive long-lived species develop cancer at surprisingly low rates. This observation, known as Peto’s paradox, has driven researchers to look for protective mechanisms built into these species’ genomes.
Recent work on whales and dolphins found that genes controlling cell-cycle checkpoints, the internal brakes that halt cell division when something goes wrong, have evolved rapidly in cetaceans. One specific mutation found in a gene called CCND1 was shown in laboratory experiments to more effectively suppress tumour-cell growth and migration. Elephants and bowhead whales appear to have independently evolved similar changes in a tumour suppressor gene, suggesting that large body size and cancer resistance co-evolved through shared genetic strategies.19PubMed Central. A Trade-Off between Body Mass and Cancer Resistance in Cetaceans Is Mediated by Cell Cycle-Related Gene Evolution Understanding how evolution has solved the cancer problem in other species could eventually inform human prevention and treatment, though that work is still in its early stages.